IR Banner

Press Releases

Date Title and Summary Additional Format
May 3, 2023
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
-- Patient Enrollment Completed in both Phase 2 OraGrowtH Trials -- -- Primary Outcome Data for both OraGrowtH Trials Expected 4Q 2023 -- -- Interim Data from OraGrowtH Trials Accepted for Presentation at PES 2023 – -- Conference Call Scheduled for Today at 4:30pm ET -- AUSTIN, Texas , May 03, 2023
Apr 27, 2023
Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)
Oral Presentation on Growth Response to LUM-201 Treatment from OraGrowtH210 Trial Interim Data from OraGrowtH212 Trial Highlighted in Poster Presentation AUSTIN, Texas , April 27, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic
Apr 19, 2023
Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
AUSTIN, Texas , April 19, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its first quarter 2023 financial results
Mar 9, 2023
Lumos Pharma to Participate in Oppenheimer’s 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023
AUSTIN, Texas , March 09, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in Oppenheimer’s 33
Mar 5, 2023
Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology
Oral Presentation Highlighting Data on 15 Subjects from OraGrowtH212 Trial Supportive of Conclusions from Interim Data Analysis Baseline Characteristics of OraGrowtH210 Trial Subjects Highlighted in Poster Presentation AUSTIN, Texas , March 05, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.
Mar 1, 2023
Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates
-- Patient Enrollment Completed in OraGrowtH210 and OraGrowtH212 Trials -- -- Primary Outcome Data for both OraGrowtH Trials Expected Q4 2023 -- -- Additional Data from OraGrowtH Trials to be Presented at IMPE 2023 -- -- Conference Call Scheduled for Today at 4:30 ET -- AUSTIN, Texas , March 01,
Feb 28, 2023
Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD
Phase 2 OraGrowtH210 and Phase 2 PK/PD OraGrowtH212 Trials Are Fully Enrolled Primary Outcome Data for Both OraGrowtH Trials Expected 4Q 2023 AUSTIN, Texas , Feb. 28, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for
Feb 15, 2023
Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023
AUSTIN, Texas , Feb. 15, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2022 financial results after
Jan 3, 2023
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
AUSTIN, Texas , Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the 12 th Annual
Dec 12, 2022
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
AUSTIN, Texas , Dec. 12, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on rare disorders, hosted two key opinion leaders (KOLs) in the field of pediatric endocrinology on December 6 th to review the Company’s interim data from two
Displaying 21 - 30 of 95